Non-small-cell lung cancers: a heterogeneous set of diseases
By Zhao Chen, Christine M. Fillmore, P. Hammerman, Carla F. Kim, Kwok-kin Wong. Nature Reviews. Cancer, 2014
1,754 citations recorded by the source corpus.
Non-small-cell lung cancers (NSCLCs), the most common lung cancers, are known to have diverse pathological features. During the past decade, in-depth analyses of lung cancer genomes and signalling pathways have further defined NSCLCs as a group of distinct diseases with genetic and cellular heterogeneity. Consequently, an impressive list of potential therapeutic targets was unveiled, drastically altering the clinical evaluation and treatment of patients. Many targeted therapies have been developed with compelling clinical proofs of concept; however, treatment responses are typically short-lived. Further studies of the tumour microenvironment have uncovered new possible avenues to control this deadly disease, including immunotherapy.
Subfields: Molecular Biology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/8b7838f18102fe0dad3172bdc5c094f397dccb0f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Hans Clevers
- H. Begthel
- R. Vries
- Alexander van Oudenaarden
- Edwin Cuppen
- Inha Heo
- R. Nusse
- Elaine Fuchs
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Long‐term expanding human airway organoids for disease modeling (2019, positive): “…(Sosnay et al , 2013) Lung cancer organoids recapitulate tumor histopathology, mutation status, and allow xenotransplantations and in vitro drug screening We next tested if AOs can be used to model lung cancer, a global respiratory disease burden (Chen et al , 2014; Ferkol & Schraufnagel, 2014).”